Alternative prevention and treatment of cardiovascular disease, Part 2

Primary Care - Clinics in Office Practice

Volumn 37, Issue 2, 2010, Pages 339-366

  Pratt, Coleman ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Daughters Charity Serv New Orleans   (United States)

Author keywords

Alternative medicine; Cardiovascular disease; Congestive heart failure; Hyperlipidemia; Hypertension; Peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ALLYL ISOTHIOCYANATE; ALPHA TOCOPHEROL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CARNITINE; CLOPIDOGREL; CRATAEGUS EXTRACT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; FOLIC ACID; GARLIC EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; PLACEBO; POLICOSANOL; POTASSIUM; PRAVASTATIN; PROPIONYLCARNITINE; SIMVASTATIN; UBIDECARENONE; UNINDEXED DRUG; WARFARIN;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DIARRHEA; DIET; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG ANTAGONISM; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HERBAL MEDICINE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE; LOW DRUG DOSE; MEDITATION; NAUSEA; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAXATION TRAINING; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SOCIAL ISOLATION; SPIRITUAL HEALING; YOGA;

CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; CORONARY ARTERY DISEASE; DIETARY SUPPLEMENTS; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; PERIPHERAL VASCULAR DISEASES; PHYTOTHERAPY; PLANT PREPARATIONS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION;

EID: 77952921256     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.02.010     Document Type: Review

References (116)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):480-486.
2. Ornish D., Brown S.E., Scherwitz L.W., et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990, 336(8708):129-133.
3. Ornish D., Scherwitz L.W., Billings J.H., et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998, 280(23):2001-2007.
4. Koertge J., Weidner G., Elliott-Eller M., et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. Am J Cardiol 2003, 91(11):1316-1322.
5. Frattaroli J., Weidner G., Merritt-Worden T.A., et al. Angina pectoris and atherosclerotic risk factors in the multisite cardiac lifestyle intervention program. Am J Cardiol 2008, 101(7):911-918.
6. Aldana S.G., Greenlaw R., Salberg A., et al. The effects of an intensive lifestyle modification program on carotid artery intima-media thickness: a randomized trial. Am J Health Promot 2007, 21(6):510-516.
7. Bucher H.C., Hengstler P., Schindler C., et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002, 112(4):298-304.
8. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989, 2(8666):757-761.
9. Burr M. Secondary prevention of CHD in UK men: the Diet and Reinfarction Trial and its sequel. Proc Nutr Soc 2007, 66(1):9-15.
10. Burr M.L., Dunstan F.D., George C.H. Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. J Membr Biol 2005, 206(2):155-163.
11. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369(9567):1090-1098.
12. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354(9177):447-455.
13. Marchioli R., Schweiger C., Tavazzi L., et al. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lipids 2001, 36(Suppl):S119-S126.
14. Singh R.B., Niaz M.A., Sharma J.P., et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian Experiment of Infarct Survival. Cardiovasc Drugs Ther 1997, 11:485-491.
15. Rakel D. Integrative medicine 2007, Saunders Elsevier, Philadelphia, p. 300. 2nd edition.
16. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995, 1271:195-204.
17. Singh R.B., Wander G.S., Rastogi A., et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1998, 12(4):347-353.
18. Singh R.B., Neki N.S., Kartikey K., et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003, 246(1-2):75-82.
19. Heck A.M., DeWitt B.A., Lukes A.L. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000, 57(13):1221-1227.
20. Linden W., Stossel C., Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996, 156(7):745-752.
21. Rees K., Bennett P., West R., et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2004, (2). CD002902. Doi: 10.1002/14651858.CD002902.pub2.
22. Manchanda S.C., Narang R., Reddy K.S., et al. Retardation of coronary atherosclerosis with yoga lifestyle intervention. J Assoc Physicians India 2000, 48(7):687-694.
23. van Dixhoorn J., Duivenvoorden H.J., Staal H.A., et al. Physical training and relaxation therapy in cardiac rehabilitation assessed through a composite criterion for training outcome. Am Heart J 1989, 118(3):545-552.
24. Ballegaard S., Borg E., Karpatschof B., et al. Long-term effects of integrated rehabilitation in patients with advanced angina pectoris: a nonrandomized comparative study. J Altern Complement Med 2004, 10(5):777-783.
25. Hambrecht R., Walther C., Möbius-Winkler S., et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004, 109(11):1371-1378.
26. Castillo-Richmond A., Schneider R.H., Alexander C.N., et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke 2000, 31(3):568-573.
27. Zamarra J.W., Schneider R.H., Besseghini I., et al. Usefulness of the transcendental meditation program in the treatment of patients with coronary artery disease. Am J Cardiol 1996, 77(10):867-870.
28. Horsten M., Mittleman M.A., Wamala S.P., et al. Depressive symptoms and lack of social integration in relation to prognosis of CHD in middle-aged women. The Stockholm Female Coronary Risk Study. Eur Heart J 2000, 21(13):1072-1080.
29. Ziegelstein R.C., Fauerbach J.A., Stevens S.S., et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000, 160:1818-1823.
30. Von Ruden A.E., Adson D.E., Kotlyar M. Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality. J Cardiovasc Pharmacol Ther 2008, 13(1):32-40.
31. Frasure-Smith N., Lespérance F., Gravel G., et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000, 101(16):1919-1924.
32. Pischke C.R., Scherwitz L., Weidner G., et al. Long-term effects of lifestyle changes on well-being and cardiac variables among coronary heart disease patients. Health Psychol 2008, 27(5):584-592.
33. Morris E.L. The relationship of spirituality to coronary heart disease. Altern Ther Health Med 2001, 7(5):96-98.
34. Gorinstein S., Jastrzebski Z., Namiesnik J., et al. The atherosclerotic heart disease and protecting properties of garlic: contemporary data. Mol Nutr Food Res 2007, 51(11):1365-1381.
35. Rahman K., Lowe G.M. Garlic and cardiovascular disease: a critical review. J Nutr 2006, 136(3 Suppl):736S-740S.
36. Verma S.K., Rajeevan V., Jain P., et al. Effect of garlic (Allium sativum) oil on exercise tolerance in patients with coronary artery disease. Indian J Physiol Pharmacol 2005, 49(1):115-118.
37. Koscielny J., Klüssendorf D., Latza R., et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis 1999, 144(1):237-249.
38. Sobenin I.A., Prianishnikov V.V., Kunnova L.M., et al. Klin Med (Mosk) 2007, 85(3):25-28. [in Russian].
39. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(7374):1202.
40. Schnyder G., Flammer Y., Roffi M., et al. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002, 40(10):1769-1776.
41. Schnyder G., Roffi M., Flammer Y., et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 2002, 288(8):973-979.
42. Wald D.S., Bishop L., Wald N.J., et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001, 161(5):695-700.
43. American Heart Association 2001 Heart and stroke statistical update 2000, American Heart Association, Dallas (TX).
44. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348:2007-2018.
45. Konstam M.A. Progress in heart failure management? Lessons from the real world. Circulation 2000, 102:1076-1078.
46. hand A., Gemmel I., Clark A.L., et al. Is the prognosis of heart failure improving?. J Am Coll Cardiol 2000, 36:2284-2286.
47. Guo R, Pittler MH, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008, 1. Art. No.CD005312. DOI: 10.1002/14651858.CD005312.pub2.
48. Tauchert M., Ploch M., Hubner W. Effectiveness of hawthorn extract LI 132 compared with ACE-I captopril: multicenter double-blind study with 1132 NYHA stage II patients. Munch Med Wochenschr 1994, 136(Suppl 1):S27-S33.
49. Tauchert M., Gildor A., Lipinski J. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure. Herz 1999, 24(6):465-474.
50. Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002, 143(5):910-915.
51. Schimidt U., Kuhn U., Hubner W.D. Efficacy of the Hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994, 1:17-24.
52. Weihmayr T., Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med 1996, 114:27-29.
53. Weikl A., Assmus K.D., Neukum-Schmidt A., et al. Fortschr Med 1996, 114:291-296. [in German].
54. Littarru G.P., Ho L., Folkers K. Deficiency of coenzyme Q10 in human heart disease: II. Int J Vitam Nutr Res 1972, 42:413-434.
55. Morisco C., Trimarco B., Cndorelli M. Effect of coenzyme Q 10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993, 71(Suppl 8):S134-S136.
56. Langsjoen P.H., Langsjoen A.M. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999, 9(2-4):273-284.
57. Suzuki Y., Masumura Y., Kobayashi A., et al. Myocardial carnitine deficiency in chronic heart failure. Lancet 1982, 1(8263):116.
58. Ferrari R., Merli E., Cicchitelli G., et al. Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004, 1033:79-91.
59. Guck T.P., Elsasser G.N., Kavan M.G., et al. Depression and congestive heart failure. Congest Heart Fail 2003, 9(3):163-169.
60. National Heart Lung and Blood Institute The Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) Available at:, Accessed January 12, 2009. http://www.nhlbi.nih.gov/guidelines/hypertension/.
61. Rouse I.L., Beilin L.J., Mahoney D.P., et al. Nutrient intake, blood pressure, serum and urinary prostaglandins and serum thromboane B2 in a controlled trial with a lacto-ovo-vegetarian diet. J Hypertens 1986, 4:241-250.
62. Sacks F.M., Kass E.H. Low blood pressure in vegetarians: effects of specific foods and nutrients. Am J Clin Nutr 1988, 48:795-800.
63. Reinhart K.M., Coleman C.I., Teevan C., et al. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Ann Pharmacother 2008, 42(12):1766-1771.
64. Silagy C.A., Neil H.A. A meta-analysis of the effect of garlic on blood pressure. J Hypertens 1994, 12(4):463-468.
65. Ried K., Frank O.R., Stocks N.P., et al. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2008, 8:13.
66. Rakel D. Integrative medicine 2007, Elsevier, Philadelphia, p. 273, 275. 2nd edition.
67. Appel L.J., Miller E.R., Seidler A.J., et al. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 1993, 153(12):1429-1438.
68. Yang H., Kenny A. The role of fish oil in hypertension. Conn Med 2007, 71(9):533-538.
69. Cappuccio F.P., MacGregor G.A. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens 1991, 9(5):465-473.
70. Dickinson HO, Nicolson DJ, Campbell F, et al. Potassium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev. 2006, 3. Art. No.CD004641. DOI: 10.1002/14651858.CD004641.pub2.
71. Whelton S.P., Hyre A.D., Pedersen B., et al. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens 2005, 23(3):475-481.
72. Rosenfeldt F., Hilton D., Pepe S., et al. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003, 18(1-4):91-100.
73. Tran M.D., Holly R.G., Lashbrook J., et al. Effects of Hatha yoga practice on the health-related aspects of physical fitness. Prev Cardiol 2001, 4:165-170.
74. Innes K.E., Bourguignon C., Taylor A.G. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review. J Am Board Fam Pract 2005, 18(6):L491-519.
75. Anderson J.W., Liu C., Kryscio R.J. Blood pressure response to transcendental meditation: a meta-analysis. Am J Hypertens 2008, 21(3):310-316.
76. Schneider R.H., Staggers F., Alexander C.N., et al. A randomised controlled trial of stress reduction for hypertension in older African Americans. Hypertension 1995, 26(5):820-827.
77. Schneider R.H., Alexander C.N., Staggers F., et al. A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year. Am J Hypertens 2005, 18(1):88-98.
78. Flaa A., Eide I.K., Kjeldsen S.E., et al. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study. Hypertension 2008, 52(2):336-341.
79. Ducher M., Fauvel J.P., Cerutti C. Risk profile in hypertension genesis: a five-year follow-up study. Am J Hypertens 2006, 19(8):775-780.
80. Rainforth M.V., Schneider R.H., Nidich S.I., et al. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep 2007, 9(6):520-528.
81. Lee H., Kim S.Y., Park J., et al. Acupuncture for lowering blood pressure: systematic review and meta-analysis. Am J Hypertens 2009, 22(1):122-128.
82. Wong N.D., Ming S., Zhou H.Y., et al. A comparison of Chinese traditional and Western medical approaches for the treatment of mild hypertension. Yale J Biol Med 1991, 64(1):79-87.
83. National Heart Lung and Blood Institute National cholesterol education program. detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Available at:, Accessed January 12, 2009. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
84. National Heart Lung and Blood Institute National cholesterol education program. ATP III guidelines at-a-glance quick desk reference Available at:, Accessed January 12, 2009. http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf.
85. Grundy S.M., Cleeman J.I., Bairey Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
86. Ferdowsian H.R., Barnard N.D. Effects of plant-based diets on plasma lipids. Am J Cardiol 2009, 104(7):947-956.
87. Koertge J., Weidner G., Elliott-Eller M., et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the multicenter lifestyle demonstration project. Am J Cardiol 2003, 91:1316-1322.
88. Banel D.K., Hu F.B. Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin Nutr 2009, 90(1):56-63.
89. Mukuddem-Petersen J., Oosthuizen W., Jerling J.C. A systematic review of the effects of nuts on blood lipid profiles in humans. J Nutr 2005, 135(9):2082-2089.
90. Slavin J.L. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 2008, 108(10):1716-1731.
91. Kerckhoffs D.A., Brouns F., Hornstra G., et al. Effects on the human serum lipoprotein profile of beta-glucan, soy protein and isoflavones, plant sterols and stanols, garlic and tocotrienols. J Nutr 2002, 132(9):2494-2505.
92. Khoo Y.S., Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 2009, 34(2):133-145.
93. Alder R., Lookinland S., Berry J.A., et al. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. J Am Acad Nurse Pract 2003, 15(3):120-129.
94. Stevinson C., Pittler M.H., Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 2000, 133(6):420-429.
95. Reinhart K.M., Talati R., White C.M., et al. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 2009, 22(1):39-48.
96. Koseoglu M., Isleten F., Atay A., et al. Effects of acute and subacute garlic supplement administration on serum total antioxidant capacity and lipid parameters in healthy volunteers. Phytother Res 2010, 24(3):374-378.
97. Liu J., Zhang J., Shi Y., et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006, 1:4.
98. Becker D.J., Gordon R.Y., Halbert S.C., et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150(12):830-839. W147-9.
99. Balk E.M., Lichtenstein A.H., Chung M., et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: an systematic review. Atherosclerosis 2006, 189(1):19-30.
100. Abumweis S.S., Barake R., Jones P.J. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008, 52. DOI:10.3402=fnr.v52i0.1811.
101. Katan M.B., Grundy S.M., Jones P., et al. Effects and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003, 78(8):965-978.
102. Castano G., Fernandez L., Mas R., et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolemia. Drugs R D 2005, 6(4):207-209.
103. Berthold H.K., Unverdorben S., Degenhardt R., et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006, 295(19):2262-2269.
104. Kassis A.N., Jones P.J. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. Am J Clin Nutr 2006, 84(5):1003-1008.
105. Chen J.T., Wesley R., Shamburek R.D., et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005, 25(2):171-183.
106. Gouni-Berthold I., Berthold H.K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002, 143(2):356-365.
107. Sontheimer D.L. Peripheral vascular disease: diagnosis and treatment. Am Fam Physician 2006, 73(11):1971-1976.
108. Murabito J.M., D'Agostino R.B., Silbershatz H., et al. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997, 96:44-49.
109. Gardner A.W., Katzel L.I., Sorkin J.D., et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc 2001, 49(6):755-762.
110. Gardner A.W., Poehlman E.T. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995, 274(12):975-980.
111. Hiatt W.R. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004, 1033:92-98.
112. Horsch S., Walther C. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD): a review based on randomized, controlled studies. Int J Clin Pharmacol Ther 2004, 42(2):63-72.
113. Pittler M.H., Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000, 108(4):341-342.
114. Rathbun S.W., Kirkpatrick A.C. Treatment of chronic venous insufficiency. Curr Treat Options Cardiovasc Med 2007, 9(2):115-126.
115. Suter A., Bommer S., Rechner J. Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: a review of 5 clinical studies. Adv Ther 2006, 23(1):179-190.
116. Pittler M.H., Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch Dermatol 1998, 134:1356-1360.